Berlin Heals Reports Positive Results from CMIC-III Heart Failure Study
Berlin Heals Holding AG has presented positive results from its CMIC-III First-In-Human study at the Heart Rhythm Society's Congress in Chicago. The study evaluated a less invasive approach to implanting the cardiac microcurrent (CMIC) device, showing significant improvements in left ventricular ejection fraction, 6-minute walk test, quality of life, and New York Heart Association class. The CMIC system was implanted via an outpatient procedure, enhancing safety and accessibility for heart failure patients. Berlin Heals plans to expand the study to include patients with mildly reduced ejection fraction and launch a double-blind sham-controlled trial across Western Europe. 
